Silybin a
CAS 22888-70-6
Silybin a (CAS 22888-70-6) is a Phase 3 pharmaceutical compound with 6 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 29114.821739130435 nM | 43 | - |
| - | IC50 | 38477.94 nM | 22 | - |
| - | AC50 | 28395.666666666668 nM | 3 | - |
| - | EC50 | 75700 nM | 1 | - |
| - | Ki | 60000 nM | 1 | - |
| - | MIC | 12.5 ug.mL-1 | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Silybin a used for in pharmaceutical contexts?
Silybin a (CAS 22888-70-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Silybin a?
No adverse-event association or SIDER side-effect rows are rendered for Silybin a in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Silybin a also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Silybin with EU status "permitted".
What clinical phase is Silybin a in?
Silybin a is rendered with ChEMBL max phase 3.